Kite Pharma

cell manufacturing

Tuesday, July 10, 2018<p>Biotech Rubius Therapeutics will invest large chunk of its recently raised $220 million to build a manufacturing …

Pharma

Gilead unit strikes out in bid to invalidate Juno cancer treatment patent

A unit of Gilead Sciences Inc on Wednesday lost a bid to invalidate a patent on a novel cancer treatment owned by the Memorial Sloan Kettering Cancer Center in New York City.<p>The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that Gilead’s …

Law

Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment

Gilead Sciences (GILD +1.4%) perks up on below-average volume in apparent response to chatter that it is nearing a settlement with Mylan NV (MYL …

Cancer Treatment

Kite Pharma continues buildout for cell therapy manufacture

Gilead Sciences' (NASDAQ:GILD) Kite Pharma has leased a 177K square-foot facility in the Netherlands for manufacturing cell therapies in Europe. The …

Business

STAT Plus: NIH is sued for plans to award exclusive license for CAR-T therapy to Gilead

A patient advocacy group has filed a lawsuit to block the federal government from awarding an exclusive license to Gilead Sciences (GILD) for an …

Immune System

Astellas sells certain U.S. research facilities to Gilead

Astellas Pharma (OTCPK:ALPMF) has agreed to sell certain Santa Monica, CA-based research facilities to Gilead Sciences' (NASDAQ:GILD) Kite Pharma …

Business

Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?

Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.<p>Arie Belldegrun is one of …

Biotechnology

They built a game-changing cancer-killing therapy. Now they’re taking on a new kind of CAR-T therapy

The two former Kite Pharma executives behind a game-changing cancer-killing technology are launching their next act: a new company to develop a suite …

Biotechnology

Pfizer to contribute assets backing CAR T developer Allogene Therapeutics

Pfizer (NYSE:PFE) inks an asset contribution agreement with CAR T developer Allogene Therapeutics under which it will contribute its portfolio of …

Biotechnology

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

NEW YORK--(BUSINESS WIRE)--<p>Regulatory News:<p>Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical …

Biotechnology

STAT Plus: CAR-T is a personalized attack on cancer. Here’s how it works

The immune system constantly scans the body for tumor cells, destroying most of them before they can become a detectable cancer, but sometimes it …

Nick's Portfolio Tournament Second Round Results

I'm going to be honest with you, ever since U.Va lost their first round game to a sixteen seed, I haven't watched a single NCAA tournament game. That …

Investing

Better Buy: Amgen Inc. vs. Gilead Sciences, Inc.

Which stock wins in a head-to-head match-up between these two big biotechs?<p><b>Amgen Inc.</b> (NASDAQ:AMGN) and <b>Gilead Sciences, Inc.</b> (NASDAQ:GILD) have …

Biotechnology

Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

A new technology that rewrites DNA could help curb cancer.<p><b>Gilead Sciences</b>' (NASDAQ:GILD) plan to transform itself into a leader in oncology treatment …

Biotechnology

Gilead Sciences' History Points to Future Success

Past could be prelude.<p>Over two and a half years ago, I wrote a story arguing that <b>Gilead Sciences</b> (NASDAQ:GILD) was incredibly undervalued at $120 a …

Biotechnology

Apple's Cure for Soaring Costs? Tech-Savvy Healthcare Clinics

Here's how the Mac maker hopes to transform healthcare.<p><b>Apple</b> (NASDAQ:AAPL) plans to open healthcare clinics for its Cupertino employees and their …

Biotechnology

Gilead Sciences: The Oncology Company?

Gilead's bold venture into adoptive cell therapy is expected to generate big profits for the biotech, but certain key challenges have to be overcome …

Biotechnology

This 'Feel Good' ETF Is A Top ETF Performer This Year

The pharma and biotech sectors have had their ups and downs over the last year as a more favorable regulatory environment has been offset by drug …

Biotechnology

Gilead Sciences: Slow Shift To Success

As <b>Gilead Sciences</b> (GILD) enters 2018, the large biotech begins a new journey. The company no longer is reliant on HCV sales and the path will survive …

Biotechnology

Sangamo in $3 billion gene-editing deal with Gilead

(Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.<p>The deal is the latest by a major drugmaker looking to develop lucrative …

Biotechnology

Gilead signs $3B licensing deal for Sangamo's gene-editing platform

Feb 22 (Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.<p>Shares of Sangamo, a California-based drug developer, rose 8.1 …

Biotechnology

Gilead is making a $3.1 billion bet on an experimental editing technology for cancer treatments

(Reuters) -U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.<p>Shares of Sangamo, a California-based drug developer, rose 8.1 percent to …

Could Aurinia Pharmaceuticals Be a Millionaire-Maker Stock?

This small-cap biotech could be on the edge of something big.<p>Plenty of small-cap biotech stocks have made millionaires out of patient investors. A …

Biotechnology

Gilead’s Kite unit signs potential $3B ZFN deal with Sangamo for oncology cell therapies

<i>By Randy Osborne, Staff Writer</i>Gilead Sciences Inc.’s Kite Pharma unit nailed down a worldwide oncology pact potentially worth more than $3 billion …

Biotechnology

5 Drugs That Are Critical for Gilead Sciences' Future

Hint: Harvoni and Truvada no longer make the list.<p><b>Gilead Sciences</b> (NASDAQ:GILD) claims a long history of blockbuster products that fueled the big …

Biotechnology

Sangamo up 6% premarket on Gilead deal to develop oncology-focused cell therapies

Sangamo Therapeutics (NASDAQ:SGMO) inks a global collaboration agreement with Gilead Sciences (NASDAQ:GILD) unit Kite Pharma aimed at developing …

Biotechnology

3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate

<b>Gilead Sciences</b>' (NASDAQ: GILD) acquisition of Kite Pharma, which closed in October, was a move generally well received among investors. The deal …

Biotechnology

How Huge Is the Latest HIV Drug Approval for Gilead Sciences?

New HIV drug Biktarvy is supposed to be Gilead's "Mount Everest." But the biotech could need need more mountains.<p><b>Gilead Sciences</b> (NASDAQ:GILD) needed …

Biotechnology

Why Biotech Stocks Soared in Trump's First Year in Office

The president deserves some of the credit. But not all of it.<p>Donald Trump was sworn in as the 45th U.S. president on Jan. 20, 2017. Even before he …

Biotechnology

Is Bellicum Pharmaceuticals, Inc. a Buy Now?

Enthusiasm for this biotech is at an all-time low. Has the market pushed the stock into bargain territory?<p><b>Bellicum Pharmaceuticals, Inc.</b> …

Biotechnology